by EpicentRx | Oct 2, 2024 | 2024, Press Releases
San Diego, October 2, 2024 – EpicentRx today announce its lead small molecule, RRx-001 (nibrozetone), is the subject of an oral nanosymposium session in amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) at the 2024 Society for Neuroscience (SfN) during...
by EpicentRx | Sep 30, 2024 | 2024, Press Releases
San Diego, Sept.30, 2024 – EpicentRx, a clinical stage biopharmaceutical company with strong momentum and big plans, will present compelling preclinical data on lead small molecule, RRx-001 (nibrozetone), in Parkinson’s Disease (PD) at the 2024 International Congress...
by EpicentRx | Sep 17, 2024 | 2024, Press Releases
The highly competitive award from the CDMRP Toxic Exposures Research Program will fund the development of EpicentRx’s small molecule, RRx-001 (nibrozetone), as a neuroprotective agent and medical countermeasure against neurotoxic chemical exposures. TORREY PINES, CA,...
by EpicentRx | Jul 30, 2024 | Company Updates
EpicentRx is elated despite this newsletter being belated. It’s already the end of July – how time does fly! The unquestioned highlight of Q2 – and possibly of all 2024 – was the BOOM! heard ‘round the world from Dr. Anthony P. Conley’s ASCO oral presentation on...
by EpicentRx | Jun 21, 2024 | Media
YouTube video interviews with Dr. Lucy Kennedy from Cleveland Clinic Development of AdAPT-001, a novel TGF-β-trap-enhanced oncolytic virus Phase I/II trial of AdAPT-001, an oncolytic virus, and a checkpoint inhibitor in solid tumors The future of AdAPT-001 in patients...
